Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research paper

Unexpected benefit of COVID-19 hospital restrictions: Reduction in patients isolating with multidrug resistant organisms after restrictions were lifted

Thomas M. Elliott a,*, Cameron Hurst a, Michelle Doidge b, Trish Hurst b,c, Patrick NA. Harris c,d, Louisa G. Gordon a,e,f

a QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, QLD 4006, Australia
b Infectious Diseases Unit, Royal Brisbane and Women’s Hospital, Herston, Brisbane, QLD 4029, Australia
c The University of Queensland, Centre for Clinical Research, Herston, Brisbane, QLD 4006, Australia
d Central Microbiology, Pathology Queensland, Royal Brisbane and Women’s Hospital, Herston, Brisbane, QLD 4029, Australia
e The University of Queensland, School of Public Health, Brisbane, QLD 4006, Australia
f Queensland University of Technology, School of Nursing, Kelvin Grove, Brisbane, QLD 4059, Australia

Received 20 May 2021; received in revised form 1 August 2021; accepted 3 August 2021

KEYWORDS
Multidrug resistant organism; COVID-19; Interrupted time series analysis

Abstract Background: During the COVID-19 pandemic, measures to prevent microorganism transmission were implemented across hospitals, including wearing compulsory surgical masks, minimising non-urgent procedures and restricting visitors. Previously, concerns have been raised that MRO-associated deaths could rise during a future pandemic through superimposed bacterial infections, inappropriate antibiotic use and reduced focus on preventing MRO infections.

Methods: In the state of Queensland, Australia with a population of 5 million, only a short first wave of coronavirus cases occurred and restrictions were quickly scaled back. This presented a natural experiment of pre-, during and post-COVID-19 restriction timings to evaluate the effectiveness of heightened prevention measures on multidrug resistant organism (MRO) infections. Patient isolation days and MRO types were collected weekly from routine infection control reports, at a large public hospital, from 28th January 2020 to 24th July 2020. In this interrupted time series design, we employed Poisson mixed effect regression modelling to evaluate the difference in incidence of patient isolation days between time periods.

Results: Compared to pre-COVID, patient isolation days reduced during COVID restrictions (incidence rate ratio 0.65, 95%CI: 0.59, 0.70; p < 0.001) and increased again post-COVID

* Corresponding author. QIMR Berghofer Medical Research Institute, Population Health, 300 Herston Rd, Herston Q4006, Brisbane, Australia. Fax: +61 7 3845 3502.
E-mail address: thomas.elliott@qimrberghofer.edu.au (T.M. Elliott).
Twitter: @ThomasMElliott1, @louisagord.

https://doi.org/10.1016/j.idh.2021.08.001
2468-0451/ © 2021 Australasian College for Infection Prevention and Control. Published by Elsevier B.V. All rights reserved.
restrictions, but did not return to pre-COVID levels (0.87, 95%CI: 0.80, 0.95; p = 0.001). The efficiency of isolating patients improved after COVID-19 with fewer bed closures required. Conclusion: Heightened infection control awareness, hand sanitation and mask wearing after COVID-19 restrictions were lifted appear to effectively prevent common hospital-acquired MRO infections.

© 2021 Australasian College for Infection Prevention and Control. Published by Elsevier B.V. All rights reserved.

Highlights

• Post COVID-19 restrictions, patient isolation days decreased by 0.87 (0.80, 0.95; p = 0.001).
• Post COVID-19, patient non-isolation room days decreased by 0.60 (0.47, 0.76; p < 0.001).
• Improved isolation efficiency for patients with MROs post COVID-19 restrictions.
• Decrease in patient isolation days was evident across all but one MRO type (VRE VAN-b).

Introduction

Termed an ‘invisible pandemic’, multidrug resistant organisms (MRO) causing infections in healthcare settings are a growing problem worldwide and result in 700,000 deaths globally each year [1]. Infections with MROs are more difficult to treat, and are associated with poorer outcomes for patients such as increased morbidity, length of stay, additional treatment and increased costs to the health care system [1]. Managing MRO aims to minimise MRO transmission through surveillance and by creating barriers between contacts. Hospitals enact this through targeted measures such as alerts and notification systems, isolating patients, hand hygiene practices and wearing personnel protective equipment. During the Coronavirus Disease 2019 (COVID-19) pandemic, several additional infection control measures were implemented across hospitals to prevent viral transmission. These included compulsory surgical masks, delaying surgeries and increasing the use of telehealth.

In Queensland Australia the first COVID-19 wave peaked in late March with around 78 cases per day. The wave was small compared with elsewhere in the world with Queensland only having 10+ cases per day for 28 days from mid-March 2020 [2]. On 23rd March 2020, Brisbane hospitals elevated their response by reducing hospital service capacity [3]. During the height of the COVID-19 response, 67% of outpatient appointments were conducted via phone or videoconferencing [4] and 50% of all elective surgery activity was suspended [5]. Due to international and interstate border closures along with ‘stay at home’ orders, the surge of COVID-19 patients in Brisbane was avoided. On the 1st June 2020, reduced patient capacity orders were reversed but universal mask wearing and hand sanitation stations across all facilities remained [5].

Previously, concerns have been raised that MRO-associated deaths could rise during a future pandemic through superimposed bacterial infections, inappropriate antibiotic use and reduced focus on preventing MRO infections [6]. However, a study during the COVID-19 pandemic showed the prolonged use of intensive preventive measures could decrease MRO burden [7]. To inform this further, here we describe a natural experiment, based on the COVID-19 experience in Brisbane, analysing pre-, during and post-COVID-19 restrictions, to evaluate the effectiveness of heightened prevention measures on MRO infections.

Methods

Study population

The study hospital is an 834-bed tertiary/quaternary facility in Brisbane with 163 isolation beds. Hospital policy is to isolate patients in single-bed isolation rooms if detected with any of: vancomycin-resistant Enterococcus (VRE) VanA resistance, VRE VanB resistance, carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenemase-producing/carbapenem-resistant Enterobacteriales (CPE/CRE), Extended spectrum beta-lactamase producing Klebsiella pneumoniae (ESBL-KP), methicillin-resistant Staphylococcus aureus United Kingdom strain 15/hospital strain (MRSA UK15/HS) and carbapenem resistant Pseudomonas aeruginosa (CRP). Risk based surveillance is undertaken with high risk wards screened regularly.

Data

Data were collected on ‘patient isolation days’ defined as the number of days where a patient was isolated due to harbouring one or more of the MROs of concern. Ward locations were collected for each patient in isolation from 28th January to 24th July 2020 (129 days), excluding weekends and public holidays. In each ward, the number of single-bed isolation rooms vary between 2 and 6, and when filled, patients are isolated in multi-bed rooms (hereafter called non-isolation rooms). Monthly occupied bed day reports were used to assess patient capacity.

T.M. Elliott, C. Hurst, M. Doidge et al.
Table 1  Average number of patients isolating per day pre-, during and post-COVID-19 restrictions.

| Ward                                      | Pre COVID-19 (1285 isolation days, 39 collection days, 28th January – 20th March 2020, average of 1007 OBD<sup>a</sup>) | During COVID-19 restrictions (953 isolation days, 47 collection days<sup>b</sup>, 26th March – 1st June 2020, average of 862 OBD<sup>c</sup>) | Post COVID-19 restrictions (1103 isolation days, 35 collection days<sup>d</sup>, 7<sup>th</sup> June – 24th July 2020, average of 1002 OBD<sup>d</sup>) |
|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Infectious Diseases                      | 6.59 (3.01)                                                                                                       | 0.79 (0.93, p < 0.001)                                                                                                       | 2.49 (1.15, p < 0.001)                                                                                                       |
| Renal/General Medicine                   | 3.18 (1.12)                                                                                                       | 1.47 (1.02, p < 0.001)                                                                                                       | 2.49 (1.15, p < 0.010)                                                                                                       |
| Respiratory                               | 3.00 (0.92)                                                                                                       | 0.53 (0.69, p < 0.001)                                                                                                       | 0.46 (0.61, p < 0.001)                                                                                                       |
| Vascular                                  | 2.97 (0.78)                                                                                                       | 0.96 (1.28, p < 0.001)                                                                                                       | 3.57 (1.29, p = 0.017)                                                                                                       |
| Colorectal                                | 2.49 (1.00)                                                                                                       | 0.96 (0.51, p < 0.001)                                                                                                       | 1.66 (0.94, p < 0.001)                                                                                                       |
| Haematology/Bone marrow transplant        | 2.46 (1.41)                                                                                                       | 3.32 (1.48, p = 0.008)                                                                                                       | 3.49 (1.69, p = 0.006)                                                                                                       |
| Orthopaedics/Trauma                      | 1.69 (1.58)                                                                                                       | 0.26 (0.53, p < 0.001)                                                                                                       | 2.03 (0.86, p = 0.266)                                                                                                       |
| Offsite                                   | 1.26 (0.55)                                                                                                       | 1.53 (0.72, p = 0.053)                                                                                                       | 0.31 (0.47, p < 0.001)                                                                                                       |
| Endocrinology/Rheumatology/General Medicine | 1.15 (1.11)                                                                                                       | 0.98 (1.07, p = 0.461)                                                                                                       | 0.94 (1.06, p = 0.407)                                                                                                       |
| Cancer Care                               | 0.87 (1.00)                                                                                                       | 0.36 (0.70, p = 0.007)                                                                                                       | 1.11 (0.72, p = 0.241)                                                                                                       |
| Gynaecology                               | 0.82 (0.60)                                                                                                       | 1.26 (1.41, p = 0.076)                                                                                                       | 1.00 (1.03, p = 0.357)                                                                                                       |
| Urology                                   | 0.77 (0.58)                                                                                                       | 0.00 (0.00, p < 0.001)                                                                                                       | 0.00 (0.00, p < 0.001)                                                                                                       |
| Burns                                     | 0.67 (0.93)                                                                                                       | 0.36 (0.49, p = 0.054)                                                                                                       | 2.14 (0.73, p < 0.001)                                                                                                       |
| Upper GI/General Surgery                  | 0.64 (0.78)                                                                                                       | 0.55 (0.72, p = 0.588)                                                                                                       | 0.97 (0.75, p = 0.067)                                                                                                       |
| Emergency and Trauma Centre               | 0.64 (1.18)                                                                                                       | 0.17 (0.43, p = 0.013)                                                                                                       | 0.29 (0.79, p = 0.137)                                                                                                       |
| Geriatric Evaluation and Management       | 0.62 (0.54)                                                                                                       | 0.70 (0.69, p = 0.525)                                                                                                       | 0.80 (0.41, p = 0.105)                                                                                                       |
| Intensive Care                            | 0.59 (0.85)                                                                                                       | 0.74 (0.99, p = 0.443)                                                                                                       | 0.74 (0.89, p = 0.451)                                                                                                       |
| Cardiology                                | 0.56 (0.79)                                                                                                       | 0.47 (0.86, p = 0.593)                                                                                                       | 0.71 (0.86, p = 0.436)                                                                                                       |
| Short stay surgical                       | 0.54 (1.05)                                                                                                       | 0.40 (0.77, p = 0.496)                                                                                                       | 1.31 (0.90, p = 0.001)                                                                                                       |
| Neurosurgery                              | 0.33 (0.48)                                                                                                       | 1.11 (0.37, p < 0.001)                                                                                                       | 0.34 (0.54, p = 0.936)                                                                                                       |
| early patient intervention centre         | 0.31 (0.52)                                                                                                       | 0.17 (0.48, p = 0.207)                                                                                                       | 0.11 (0.32, p = 0.062)                                                                                                       |
| Ear, nose & throat                        | 0.28 (0.86)                                                                                                       | 0.66 (0.60, p = 0.019)                                                                                                       | 0.60 (0.69, p = 0.086)                                                                                                       |
| Other                                     | 0.26 (0.64)                                                                                                       | 0.11 (0.31, p = 0.158)                                                                                                       | 0.06 (0.24, p = 0.085)                                                                                                       |
| Stroke                                    | 0.18 (0.60)                                                                                                       | 0.23 (0.52, p = 0.653)                                                                                                       | 0.20 (0.41, p = 0.866)                                                                                                       |
| Maternity                                 | 0.08 (0.27)                                                                                                       | 0.13 (0.34, p = 0.450)                                                                                                       | 0.11 (0.32, p = 0.590)                                                                                                       |
| Intensive Care Nursery                    | 0.00 (0.00)                                                                                                       | 0.00 (0.00, p = n/a)                                                                                                        | 0.57 (0.92, p < 0.001)                                                                                                       |
| MRO type                                  | MRSA -UK15/HS                                                                                                     | 7.54 (1.59)                                                                                                                  | 2.62 (2.01, p < 0.001)                                                                                                       |
|                                          | VRE-VAN A                                                                                                         | 7.10 (2.15)                                                                                                                  | 3.16 (1.78, p < 0.001)                                                                                                       |
|                                          | VRE-VAN B                                                                                                         | 6.36 (1.51)                                                                                                                  | 5.78 (2.09, p = 0.149)                                                                                                       |
|                                          | ESBL - KP                                                                                                         | 6.23 (2.18)                                                                                                                  | 4.88 (1.51, p < 0.001)                                                                                                       |
|                                          | CRP                                                                                                                | 2.36 (0.99)                                                                                                                  | 1.54 (1.09, p < 0.001)                                                                                                       |
|                                          | CPE/CRE                                                              | 1.64 (0.78)                                                                                                                  | 0.68 (0.71, p < 0.001)                                                                                                       |
|                                          | PCP                                                                                                                | 0.95 (1.57)                                                                                                                  | 0.12 (0.33, p < 0.001)                                                                                                       |
|                                          | CRAB                                                                                                               | 0.64 (0.78)                                                                                                                  | 0.12 (0.33, p < 0.001)                                                                                                       |
|                                          | VRE-VAN A&B                                                         | 0.13 (0.47)                                                                                                                  | 0.14 (0.35, p = 0.892)                                                                                                       |
|                                          | Other                                                                | 0.00 (0.00)                                                                                                                  | 0.02 (0.14, p = n/a)                                                                                                        |

Abbreviations: OBD = occupied bed days; GI = gastrointestinal; n/a = not applicable; VRE = vancomycin-resistant Enterococcus, CRAB = Carbapenem-resistant Acinetobacter baumannii; CPE = Carbapenemase-Producing Enterobacteriales; ESBL – KP = Extended spectrum beta-lactamase Klebsiella pneumoniae; MRSA Methicillin-resistant Staphylococcus aureus; UK15 = United kingdom strain 15; HS = hospital strain; CRP = carbapenem resistant Pseudomonas; PCP = Pneumocystis pneumonia.

<sup>a</sup> Six days between restriction periods were not included in analysis in order to let the prevention measures impact patients.

<sup>b</sup> Monthly occupied bed days were: January – 1008; February – 1011; March – 1002; April – 837; May – 853; June – 1159; July – 853.

<sup>c</sup> With VRE Van-b removed from analysis no difference between scenarios were present.

**Analysis**

In this interrupted time-series design, a Poisson mixed-effect regression analysis was employed to evaluate the difference in patient isolation days between the pre-, during and post-COVID-19 restriction time periods. Ward was used as the random effect in the Poisson mixed effect regression to account for potential clustering effect at this level, and isolation events were offset by the occupied bed days to calculate incidence rate ratios (IRR). We also assessed the subset of non-isolation room patient days. The time periods comprised 39 days in pre-; 47 days during; and
35 days post-COVID-19 restrictions. We hypothesized immediate decreases (level change) in outcomes and no continued decrease over time (i.e., slope change). The validity of the Poisson mixed-effect model was evaluated by inspecting the model residuals and the presence autocorrelation. All statistical analyses were conducted using Stata v15.0 software (StataCorp, College Station, TX).

**Results**

In total there were 1285 patient isolation days in the pre-, 856 during and 998 post-COVID-19 restriction time periods (Table 1). The rate of patient isolation was substantially lower during COVID-19, with isolation during this period being approximately two-thirds of that observed pre-COVID-19 (IRR = 0.65; 95%CI: 0.59, 0.70; p < 0.001)

Compared to pre-COVID-19, there was a decrease in patient isolation days post COVID-19 restrictions with an IRR of 0.87 (95%CI: 0.80, 0.95; p = 0.001) (Fig. 1). In the non-isolation room subset, we found 200 patient isolation days pre-, 58 during and 117 post-COVID-19 restriction time periods.

Compared to pre COVID-19, there were decreases in non-isolation room days with IRRs of 0.17 (95%CI: 0.12, 0.25; p < 0.001) during COVID-19 restrictions and 0.60 (95%CI: 0.47, 0.76; p < 0.001) post COVID-19 restrictions (Fig. 1).

Patient isolation days attributed to VRE VAN-b were uniquely not impacted during COVID-19 restrictions and increased after restrictions were lifted (Table 1). Patient isolation days decreased in both during and post-COVID-19 restriction periods across five wards, while increases in VRE VAN-b led to increased isolation days in Haematology and Vascular wards (Table 1).

**Discussion**

We identified an overall decrease in the number of patients isolating with MROs during the COVID-19 restrictions that subsequently rose after the restrictions were lifted but did not return to pre-COVID-19 levels. This decrease was evident across all but one MRO type. We highlight improved isolation efficiency with the continued decrease in non-isolation room use for isolating patients with MROs. If maintained post pandemic, this improved isolation efficiency could save AUS$4,692 per month in hospital costs through reducing closure of multi-bed rooms.

Three studies have investigated the heightened precautions associated with COVID-19 and its impact on incidence of MROs. An Italian study found a significant reduction in the incidence of total MRO infections during the pandemic compared to previous years [7]. Similar to our study, no changes in detection of *Enterococcus faecium* infections were identified during COVID-19 restrictions. Also similar to our findings, in a Belgian study, no differences in the acquisition rate of MROs in the intensive care unit (ICU) were found before and during the COVID-19 pandemic [9]. This may be explained by the heightened prevention measures already occurring for patients within an ICU. Within an Italian geriatric population, increased MRO bloodstream infections and mortality were identified in a post COVID-19 outbreak period [10]. However, the small selective sample size (83 cultures) and incomplete screening limits the generalizability of these results. We conclude from these studies that a holistic approach is required to understand the impact of COVID-19 precaution measures, rather than within a specific ward.
The limitations of this study were the lack of patient-level data and brevity of data collection to further explore this topic. We cannot rule out the impact of changes in patient case mix or other service-line factors (e.g., volume of transplants) that may affect the susceptibility of patients to MROs. Seasonality was not included in the interrupted time-series design, although the impact should be minimal with influenza season not occurring. Balanced against these limitations, was access to patient isolation data before, during and after a COVID-19 wave at a large public hospital.

We have shown a hospital committed to reduced microorganism transmission, as occurred during COVID-19 pandemic, can immediately reduce the MRO burden, with potential ongoing improvements in MRO prevention and patient isolation efficiency.

Ethics

No patient information was collected during this study, hence patient consent was not required. Data collected in this study was approved by the QIMR Berghofer Medical Research Institute Human Research Ethics Committee (P2353) and the Queensland Government Public Health Act Human Research Ethics Committee (RD007427).

Authorship statement

Thomas Elliott: Conceptualization, Methodology, Formal analysis, Writing - Original Draft.
Cameron Hurst: Formal analysis, Writing - Review & Editing.
Michelle Doidge: Resources, Investigation.
Trish Hurst: Resources, Investigation.
Patrick NA Harris: Supervision, Writing - Review & Editing.
Louisa G Gordon: Conceptualization, Writing - Original Draft, Writing - Review & Editing, Supervision.

Conflict of interest

No author had any conflicts of interest.

Funding

This study was supported by Queensland Genomics, Queensland Health, Queensland Government, Australia.

Provenance and peer review

Not commissioned; externally peer reviewed.

References

[1] O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on antimicrobial resistance; 2016.
[2] Queensland Government. Queensland COVID-19 statistics. 2021.
[3] Drummond S. 27 March 2020 - COVID-19 (coronavirus) message from the Chief Executive. In: Metro north hospital and health service; 2020.
[4] The Metro North Hospital and Health Service. Metro north hospital and health service. Annu Rep 2020:2019–20.
[5] Miles S. Quarter of a billion dollar elective surgery blit. In: Directory TCqAm, editor. Queensland government; 2020.
[6] Chibabhai V, Duse AG, Perovic O, Richards. GA Collateral damage of the COVID-19 pandemic: exacerbation of antimicrobial resistance and disruptions to antimicrobial stewardship programmes? South African Med J = Suid Afrikaanse Tydskrif Geneeskunde 2020;110:572–3.
[7] Bentivegna E, Luciani M, Arcari L, Santino I, Simmaco M. Martelletti P. reduction of multidrug-resistant (MDR) bacterial infections during the COVID-19 pandemic: a retrospective study. Int J Environ Res Publ Health 2021:18.
[8] Page K, Barnett AG. Graves N. What is a hospital bed day worth? A contingent valuation study of hospital Chief Executive Officers. BMC Health Serv Res 2017;17:137.
[9] Bogossian EG, Taccone FS, IZZI A, Yin N, Garufi A, Hublet S, et al. The acquisition of multidrug-resistant bacteria in patients admitted to COVID-19 intensive care units: a monocentric retrospective case control study. Microorganisms 2020; 8.
[10] Gasperini B, Cherubini A, Lucarelli M, Espinosa E, Prospero E. Multidrug-resistant bacterial infections in geriatric hospitalized patients before and after the COVID-19 outbreak: results from a retrospective observational study in two geriatric wards. Antibiotics 2021;10.